Summary of data to be collected
| Baseline | 3 years | |
| Baseline demographic | ||
| Sex (M/F) | X | – |
| Age (years) | X | – |
| Labour market affiliation | X | – |
| Duration of pain (weeks) | X | – |
| Level of education (primary or high school, medium-term or long higher education) | X | – |
| Marital status (married, cohabiting, separated/divorced, widowed, single) | X | – |
| Outcome of clinical assessment (pain diagnosis) | X | – |
| Other inflammatory or degenerative rheumatic diseases (y/n) | X | – |
| Baseline analgesics: | ||
| Use of mild analgesics, including NSAIDs (y/n) | X | – |
| Use of anti-rheumatics (y/n) | X | – |
| Use of antidepressant for example, Amitriptyline (y/n) | X | – |
| Use of antiepileptics, for example, Gabapentin (y/n) | X | – |
| Use of muscle relaxants for example, Chlorzoxazone (y/n) | X | – |
| Low dose naltrexone (y/n) | X | – |
| Use of Cannabinoids (y/n) | X | – |
| Clinical examination: | ||
| Tender point count (0–18) | X | – |
| Patient-reported outcomes: | ||
| FIQR | X | – |
| PSEQ | X | – |
| PDQ | X | – |
| SSS | X | – |
| WPI | X | – |
| Official registryextraction: | ||
| DREAM database | X | X |
| Integrated Labour Market Database | X | X |
FIQR, Fibromyalgia Impact Questionnaire; M/F, Male/Female; PDQ, Pain Detect Questionnaire; PSEQ, Pain Self Efficacy Questionnaire; SSS, Symptom Severity Scale; y/n, yes/no; WPI, Widespread Pain Index.